Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of carboxymethylcellulose (an artificial tear/eye lubricant), cyclosporine (an immunosuppressant), and vitamin D (a fat-soluble vitamin). The combination is used for treating dry eye disease (DED), particularly in patients with vitamin D deficiency. Carboxymethylcellulose acts as a lubricant providing temporary relief from burning and discomfort due to eye dryness. Cyclosporine works by suppressing T-cell activation involved in ocular surface inflammation, helping to maintain a more stable tear film. Vitamin D supplementation has been shown to lead to earlier and significant improvement in tear film stability and tear production in vitamin D deficient dry eye patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylcellulose + cyclosporine + vitamin d.